Matches in Nanopublications for { <http://bio2rdf.org/drugbank_resource:DB00611_DB06274> ?p ?o ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- drugbank_resource:DB00611_DB06274 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00611_DB06274 label "DDI between Butorphanol and Alvimopan - Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan. [drugbank_resource:DB00611_DB06274]" assertion.
- drugbank_resource:DB00611_DB06274 identifier "drugbank_resource:DB00611_DB06274" assertion.
- drugbank_resource:DB00611_DB06274 title "DDI between Butorphanol and Alvimopan - Opioid analgesics such as butorphanol may enhance the adverse/toxic effect of alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation. According to alvimopan prescribing information, alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation. Monitor for increased alvimopan adverse effects in patients using opioids prior to alvimopan." assertion.